In Vivo CAR-T

In vivo CAR-T is the route in E235｜20年内CAR-T治愈癌症？与刘诚博士聊聊癌症治疗的底层哲学 where the CAR-T manufacturing process is moved from the laboratory into the patient. Instead of extracting immune cells, engineering them outside the body, and reinfusing them, an injectable gene-delivery tool modifies target immune cells inside the body so they become [[CARTCellTherapy|CAR-T]] cells.

The episode explains why big pharma interest is high: in vivo CAR-T could make a personalized cell therapy look more like a scalable drug, reducing time, logistics, and manufacturing cost. [[LiuCheng|刘诚]] still treats it as early and technically risky. The central problems are cell specificity, because the tool should modify T cells rather than unrelated tissue cells, and dose control, because clinicians cannot directly count the final number of qualified CAR-T cells produced inside the patient.

Key Claims

• In vivo CAR-T is attractive because it could remove much of the Ex Vivo CAR-T Manufacturing cycle.
• It still uses the patient’s own immune cells, so its promise is not the same as Allogeneic CAR-T.
• The source says the route may reduce per-patient manufacturing cost by roughly an order of magnitude, but that estimate remains source-scoped.
• In vivo delivery changes the production route; it does not automatically solve cancers that current CAR-T Cell Therapy cannot treat.
• The route still has to solve Solid Tumor CAR-T Constraints, Tumor Microenvironment suppression, and Cytokine Release Syndrome safety.

Connections

• CAR-T Cell Therapy and Cancer Immune Recognition Problem - therapy logic being moved into an in-body manufacturing process.
• Ex Vivo CAR-T Manufacturing and Allogeneic CAR-T - alternative production and sourcing models.
• [[LiuCheng|刘诚]] and Eureka Therapeutics - source viewpoint and company context.
• China Cell Therapy Regulatory Dual Track - regulatory context if in vivo cell therapy moves from clinical exploration to broad commercialization.